PRC2 inhibitors patented by Shanghai Institute of Materia Medica, Suzhou Suplead Life Sciences Sep. 9, 2019
Phase II results support further study of AAV2-REP1 gene therapy in patients with choroideremia Sep. 9, 2019
Epigenetic inactivation of CELF2 associated with shorter overall survival in breast cancer Sep. 9, 2019
RSS